I promise I’ll put down the edibles, but hear me out: if the active pharmaceutical ingredient (API) constitutes 52% of the production costs of US-made drugs, then a country with no notable paracetamol API capacity is in for a bad time.
According to this: India and the EU dominate API manufacturing for the most-used ATC-3 therapeutic classes in the U.S. market | Quality Matters | U.S. Pharmacopeia Blog the US local capacity is concentrated around cheaper additives and supplements - multivitamins, etc…
Just judging on the major Panado players like China and India, Kenvue (the now US-owned artist formerly in the J&J superband) would be facing Tylenol production cost increases of between 10- and 127% just because of the spike in raw material tariffs.
Kenvue’s share price has recovered since the brainworm farts from the US health department, but it is an interesting rabbit hole.